Business context and reporting period
uniQure N.V. is a Netherlands-based gene-therapy company. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2023. HEMGENIX, its hemophilia B gene therapy, is commercialized by CSL Behring; uniQure manufactures it and is entitled to royalties and certain milestones. Its development pipeline includes AMT-130 for Huntington’s disease, AMT-162 for SOD1-ALS, and preclinical programs including temporal lobe epilepsy and Fabry disease.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $2.4 million | $0.5 million | $7.7 million | $2.3 million |
| Operating expenses | $68.6 million | $59.5 million | $149.7 million | $115.5 million |
| Loss from operations | $65.1 million | $56.1 million | $139.2 million | $110.1 million |
| Net loss | $68.5 million | $39.1 million | $145.7 million | $85.7 million |
| Basic and diluted loss per share | $1.44 | $0.84 | $3.06 | $1.84 |
Revenue remains small relative to operating costs, so the company remains loss-making and reports no meaningful positive operating margin. H1 2023 revenue included $0.8 million in license royalties, $6.2 million in contract manufacturing revenue, and $0.7 million in collaboration revenue. HEMGENIX’s first U.S. sale triggered a $100 million milestone receivable, collected in July 2023; it was not cash at June 30.
At June 30, cash and cash equivalents were $513.6 million, current investment securities $115.0 million, and restricted cash $3.2 million. Cash, restricted cash and investment securities totaled $631.8 million. Total current assets were $757.0 million and current liabilities $68.4 million. Shareholders’ equity was $353.3 million, down from $476.0 million at year-end 2022; accumulated deficit was $727.6 million.
H1 operating cash use was $135.3 million, versus $41.4 million in H1 2022. Investing activities generated $48.8 million, mainly from investment-security maturities; financing activities generated $370.3 million, chiefly from the royalty financing. Cash, cash equivalents and restricted cash ended the period at $516.8 million.
Debt included $100.0 million principal owed to Hercules, with a reported long-term debt carrying amount of $101.1 million. The May royalty financing was recorded as debt, with a June 30 carrying amount of $372.4 million. Total liabilities were $589.4 million.
Material changes versus the prior comparable period
- H1 revenue rose $5.5 million, primarily because HEMGENIX royalties and contract manufacturing revenue began to be recognized; collaboration revenue fell, partly following termination of the BMS agreements in February 2023.
- H1 R&D expense increased $15.7 million to $106.8 million, including $10.6 million related to the AMT-162 license and increases in personnel and facility costs. SG&A rose $15.6 million to $39.0 million, including CSL-related financial advisory fees and higher personnel, professional and other costs.
- H1 net loss increased $60.0 million. In addition to higher operating costs and interest expense, prior-year results included a $28.0 million foreign-currency gain, compared with a $2.0 million loss in 2023.
- Cash and investments increased from $392.8 million at December 31, 2022 to $628.6 million at June 30, 2023, chiefly reflecting the royalty financing and, after quarter-end, collection of the $100 million CSL milestone. The royalty financing increased liabilities and future royalty-related financing costs.
Outlook, commentary and key risks
- Management believes cash and cash equivalents and investment securities will fund operations into the second quarter of 2026. It expects expenses to rise as it advances AMT-130 toward Phase III and other programs toward clinical studies. This runway estimate depends on assumptions and is not a profitability forecast.
- In May 2023, uniQure received $375 million gross, or approximately $370.1 million net, for selling the lowest royalty tier on HEMGENIX sales. The purchaser is entitled to 1.85 times the upfront payment ($693.8 million) through June 30, 2032; if that cap is not reached, the return may rise to 2.25 times ($843.8 million) through December 31, 2038. An additional $25 million payment is conditional on specified 2024 sales; terms also provide for a contingent payment in certain circumstances if the sales threshold is not met. The company retains other royalties and CSL contractual milestones of up to $1.5 billion. Management expects an effective interest rate of approximately 12.0%–13.5% on the financing.
- The Hercules facility maturity and interest-only period were extended to January 5, 2027. The company must repay $100 million principal at maturity and comply with cash-location, minimum-cash and other covenants; it reported material covenant compliance at June 30. The lender has security over substantially all assets, subject to stated exclusions.
- June interim AMT-130 data came from small Phase I/II cohorts and included comparisons with natural history. The company reported generally manageable tolerability and exploratory clinical-function trends, but biomarker results varied by dose. The filing cautions that interim results may change and may not predict later-stage efficacy or approval.
- Key risks include clinical-trial safety, efficacy, timing and enrollment; gene-therapy manufacturing and regulatory requirements; reliance on collaborators and third parties; intellectual-property disputes; reimbursement, pricing and competition; and the possibility of needing additional capital on acceptable terms. AMT-260 contingent consideration was valued using assumptions about its progress into clinical development, making the liability sensitive to those estimates.
Important facts for investors to verify
- Progress, safety findings and subsequent data from AMT-130, and the evidence and regulatory path needed for Phase III.
- HEMGENIX commercial sales, royalties retained after the royalty sale, the conditional 2024 sales payment, and the timing and amount of future CSL milestones.
- Cash burn against management’s second-quarter-2026 runway estimate, including clinical spending, manufacturing costs and milestone obligations.
- The royalty financing’s actual repayment trajectory, effective interest rate and ultimate cost compared with its contractual caps.
- Hercules covenant compliance, liquidity restrictions and the ability to meet debt and contingent milestone obligations.
- Whether increased revenue and clinical progress can offset continuing losses and rising R&D and SG&A costs.